OTCQB:PBIO - Post Discussion
Post by
AveragePenny on Apr 14, 2023 11:19am
Pressure BioSciences, Inc. Reports Q4 and FY 2022 Financial
Financial Results: Q4 2022 vs. Q4 2021 (rounded to nearest thousand, except EPS)
- Total revenue for Q4 2022 was $607,000 compared to $315,000 for Q4 2021, an increase of 93%.
- Instrument sales for Q4 2022 were $230,000 compared to $116,000 for Q4 2021, an increase of 98%.
- Consumable sales for Q4 2022 were $92,000 compared to $83,000 for Q4 2021, an increase of 11%.
- PBI Agrochem subsidiary sales in Q4 2022 were $71,000 compared to $12,000 for Q4 2021, an increase of 500%.
- Operating loss for Q4 2022 was $1,546,000 compared to $1,221,000 for Q4 2021, an increase of 27%, including an increase in PBI Agrochem inventory reserves of $640,000.
- Basic and diluted net loss per share was $(0.38) for Q4 2022, improved from $(0.57) for Q4 2021.
Financial Results: FY 2022 vs. FY 2021 (rounded to nearest thousand, except EPS)
- Total revenue for 2022 was $1,729,000 compared to $2,002,000 for 2021, a decrease of 14%.
- Instrument sales for 2022 were $724,000 compared to $1,047,000 for 2021, a decrease of 31%.
- Consumable sales for 2022 were $257,000 compared to $274,000 for 2021, a decrease of 6%.
- PBI Agrochem subsidiary sales in 2022 were $165,000 compared to $29,000 for 2021, an increase of 466%.
- Operating loss for 2022 was $4,898,000 compared to $4,185,000 for 2021, an increase of 17%, including an increase in our PBI Agrochem inventory reserves of $640,000.
- Basic and diluted net loss per share was $(1.68) for 2022, improved from $(3.42) for 2021.
Be the first to comment on this post